Loading
Loading
Research Overview
Synthetic CNTF-mimetic peptide; activates JAK/STAT and MAPK signalling cascades associated with neurogenesis, neuronal survival, and differentiation via partial CNTF receptor complex engagement.
P-21 is a short synthetic peptide engineered to mimic the biological activity of ciliary neurotrophic factor (CNTF) — a neurotrophic cytokine involved in neuronal survival, differentiation, and neurogenesis. The compound activates overlapping downstream signalling pathways to CNTF, including JAK/STAT and MAPK cascades, without requiring full CNTF receptor complex engagement.
Preclinical research has used P-21 in neurogenesis models, examining hippocampal neurogenesis markers, cognitive performance in aged animals, and neuroprotective responses in neurodegenerative disease contexts. The research rationale is grounded in the well-established role of CNTF pathway activation in supporting neuronal populations and potentially countering neurodegeneration.
P-21 is administered subcutaneously in animal research protocols with a half-life of hours. No human dose-finding, safety, or efficacy data have been published. It remains firmly in early preclinical research classification and is not an established protocol compound.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, p-21 has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
P-21 research is most relevant to protocols examining:
CNTF pathway neurogenesis and hippocampal proliferation research
Neurodegenerative disease model investigations
JAK/STAT neuronal survival signalling studies
Researchers studying CNTF receptor complex engagement without full-length CNTF
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Synthetic CNTF-mimetic peptide; activates JAK/STAT and MAPK signalling cascades associated with neurogenesis, neuronal survival, and differentiation via partial CNTF receptor complex engagement.
| Parameter | Value |
|---|---|
| Dose range | No human protocol established |
| Schedule | Daily (animal models) |
| Route | Subcutaneous |
| Half-life | ~Hours |
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.